title: Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow.
abstract: We have investigated the effects of different growth factors on the proliferation and osteogenic potential of primary cultures of human bone marrow stromal cells (BMSC). Fibroblast growth factor (FGF)-2 was the most effective in promoting growth of these cells in vitro. The size of colonies formed in clonal conditions was approximately 2.5 times larger in presence of FGF-2. Also the morphology of BMSC was affected: cells cultured in 10% FCS alone became flattened, whereas FGF-2 expanded cells maintained a fibroblast-like elongated phenotype. Levels of alkaline phosphatase activity in BMSC expanded with FGF-2 were significantly lower (56%) than control and, after stimulation with ascorbic acid, betaGlycerophosphate and dexamethasone, FGF-2 expanded BMSC deposited approximately 3-fold more mineralized matrix than control cells. We have assessed osteogenicity of BMSC on hydroxyapatite porous scaffolds (bioceramics) by an ectopic bone formation assay. FGF-2 expanded BMSC yielded a higher bone formation (>20-fold) than control cells. We conclude that FGF-2, promoting BMSC proliferation, maintains cells in a more immature state allowing in vitro expansion of human osteo-progenitors which, associated with bioceramics, can differentiate in vivo and form bone tissue.
authors.affiliation: Laboratorio di Differenziamento Cellulare, Istituto Nazionale per la Ricerca sul Cancro/Centro di Biotecnologie Avanzate, Genova, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Muraglia
authors.forename: G
authors.initials: G
authors.lastname: Campanile
authors.forename: R
authors.initials: R
authors.lastname: Cancedda
authors.forename: R
authors.initials: R
authors.lastname: Quarto
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000032:analysis; D001205:Ascorbic Acid / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects / Q000201:enzymology; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D002648:Child; D003907:Dexamethasone / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D005994:Glycerophosphates / Q000494:pharmacology; D013006:Growth Hormone / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: D005994:Glycerophosphates; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D003907:Dexamethasone; D013006:Growth Hormone; D000469:Alkaline Phosphatase; D001205:Ascorbic Acid